Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Instil Bio, Inc.
(NQ:
TIL
)
21.20
-0.23 (-1.05%)
Streaming Delayed Price
Updated: 10:24 AM EST, Dec 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Instil Bio, Inc.
< Previous
1
2
3
4
Next >
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
From
Instil Bio
Via
GlobeNewswire
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
October 24, 2024
This drugmaker's lead candidate could become a top-selling cancer therapy.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 08, 2024
Via
Benzinga
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
September 25, 2024
These relatively small companies are developing new cancer therapies that could generate billions in annual sales.
Via
The Motley Fool
Steelcase Reports Weak Sales, Joins American Healthcare REIT And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
September 19, 2024
Via
Benzinga
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2024
August 13, 2024
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
March 21, 2024
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 17, 2024
Via
Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
September 17, 2024
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock.
Via
The Motley Fool
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
September 16, 2024
Via
Benzinga
Exposures
Fossil Fuels
iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
September 16, 2024
Via
Benzinga
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
September 16, 2024
From
Instil Bio
Via
GlobeNewswire
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
December 13, 2023
TIL stock results show that Instil Bio beat analyst estimates for earnings per share the second quarter of 2023.
Via
InvestorPlace
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
September 14, 2024
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy.
Via
The Motley Fool
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
September 12, 2024
Via
Benzinga
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 13, 2024
From
Instil Bio
Via
GlobeNewswire
Week In Review: ImmuneOnco Out-Licenses Two Antibodies In $2 Billion Deal
August 03, 2024
Shanghai ImmuneOnco Biopharma out-licensed global rites (ex-China) for two of its antibodies to Instil Bio of Dallas, Texas. ImmuneOnco will receive an upfront and near-term payments of $50 million,...
Via
Talk Markets
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
August 01, 2024
From
Instil Bio
Via
GlobeNewswire
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 12, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 12, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via
InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
May 10, 2024
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 10, 2024
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Strategic Update
January 16, 2024
From
Instil Bio
Via
GlobeNewswire
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
December 13, 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the first quarter of 2023.
Via
InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
December 13, 2023
TIL stock results show that Instil Bio missed analyst estimates for earnings per share the third quarter of 2023.
Via
InvestorPlace
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
December 05, 2023
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
November 06, 2023
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
Instil Bio
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
June 29, 2023
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.